Can COVID Vaccine Makers Benefit From the Biden Administration?

1 min read

In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss the implications of President Joe Biden’s administration buying an additional 200 million doses of coronavirus vaccines, split between Moderna (NASDAQ: MRNA) and the duo of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). On Feb. 11, Biden announced that deals had been finalized with the companies, although critical details of pricing were left out. The additional doses are expected to be delivered by the end of July.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Virgin Galactic Delays Much-Anticipated Weekend Test Flight

Next Story

5 Renewable Energy Stocks to Consider Buying Right Now

Latest from Blog